( continued from page 19)
This structured approach functions as a cognitive map. It is intended to be flexible, usable within a few minutes and compatible with the realities of busy primary care settings.
Prioritizing What Matters Most
A key feature of the EATH framework is its emphasis on eating behavior as the primary entry point. Before addressing metabolic factors or prescribing pharmacotherapy, the clinician must first understand the patient’ s relationship with food. Disordered eating that is not identified prior to initiating GLP-1 therapy may be amplified by the medication’ s appetite-suppressing effects, creating the appearance of therapeutic success while concealing serious nutritional compromise.
If eating behavior is identified as disordered( characterized by restriction, binging, purging or rigid behavioral control) the clinical focus shifts immediately toward psychiatric risk stratification and early involvement of mental health and nutrition specialists. This step helps differentiate structured dietary restriction from pathological restriction, a distinction that requires attention to rigidity, emotional valence and the degree to which behavior is driven by fear or compulsion rather than deliberate choice.
When eating behavior appears within normal parameters, the clinician then evaluates for addictive and compulsive patterns. Laxative misuse, stimulant use and compulsive exercise are frequently overlooked in primary care because they are often concealed, normalized by the patient or framed as health-promoting behaviors. Direct, nonjudgmental inquiry is essential.
The Role of Trauma, Body Image and Hormonal Factors
EATH also emphasizes that disordered eating does not arise in isolation. Trauma history, body image disturbance and hormonal conditions represent critical contextual factors that shape symptom expression and treatment response. Women with a history of adverse childhood experiences or interpersonal trauma are at elevated risk for eating disorders, particularly those characterized by loss of control or behavioral rigidity as coping mechanisms.
Polycystic ovary syndrome represents a particularly important intersection of biological and psychological vulnerability. Patients with PCOS experience insulin resistance, weight gain and hormonal imbalance, all of which contribute to body image distress and elevated rates of disordered eating. The introduction of pharmacologic weight loss therapies in this context can be metabolically beneficial but must be accompanied by systematic behavioral screening and ongoing monitoring.
The final domain, hormonal and metabolic factors, reminds clinicians that weight-related symptoms do not always arise from behavioral causes alone. Thyroid dysfunction, adrenal dysregulation and medication effects can produce or exacerbate disordered eating patterns and must be evaluated as part of a comprehensive workup.
A Brief Screening Tool for Clinical Practice
To operationalize the framework, a brief structured screener can be implemented as part of routine primary care visits. A practical screener for this population covers five clinical domains:
» Eating patterns and rigidity – including self-imposed food rules, avoidance behaviors and emotional responses to eating
» Compensatory behaviors – including laxative use, self-induced vomiting and stimulant misuse
» Body image distress – and its impact on daily functioning and self-worth
» Substance use – with particular attention to use for appetite control or weight management purposes
» Pharmacologic context – including current or recent use of GLP-1 receptor agonists or other weight loss agents
Completion time is approximately three to five minutes, making it practical for use in primary care. Rather than generating a categorical diagnosis, the instrument provides a risk-stratified clinical orientation. It highlights where concern is concentrated – toward eating disorder pathology, compulsive behavior, substance use risk or hormonal complexity – and guides the clinician toward focused questioning, appropriate baseline workup or timely referral.
GLP-1 Therapies and Psychiatric Complexity
GLP-1 receptor agonists and related pharmacologic agents have transformed obesity management, offering weight reduction previously achievable only through bariatric surgery. For many patients, these medications improve metabolic parameters, reduce cardiovascular risk and support meaningful quality-of-life changes. However, their mechanisms of action – particularly appetite suppression and altered reward pathway signaling – intersect directly with pathways involved in eating disorders and addictive behaviors.
In patients with underlying vulnerability, these effects may amplify restrictive tendencies or mask problematic eating patterns. The pharmacologically induced absence of hunger can be experienced psychologically as mastery or control, reinforcing disordered restriction and delaying recognition of inadequate nutritional intake. Poison control centers have reported a nearly 1,500 percent increase in calls related to GLP- 1 overdose or adverse effects since 2019, underscoring the urgency of pre-prescribing behavioral assessment.
These dynamics do not contraindicate GLP-1 use but make careful patient selection and ongoing monitoring essential. The clinician must remain attentive not only to weight and metabolic markers but also to behavioral and psychological changes throughout the course of treatment.
Clinical Pearls
· Begin every weight-related visit by assessing the patient’ s relationship with food.
· Differentiate structured dieting from pathological restriction.
20 LOUISVILLE MEDICINE